EPCORITAMAB BISPECIFIC

Bispecifics really are a game changer. After twelve weekly treatments at the wonderful Christie in Manchester with Epcoritamab along with Lenalidomide, I’ve just had a new PET-CT scan showing “complete metabolic response”.

Report text: “Sites of nodal disease in the neck, upper retroperitoneum, mesentery, bilateral external iliac regions and left groin have significantly reduced in size and activity with some now unmeasurable and all residual activity is now below background blood pool activity. Complete metabolic response. Deauville score 2”.

A PET-CT five months ago showed extensive disease in all the above areas, with the retroperitoneum disease extending 27cm and SUVmax figures of 14.0, 10.5 and 11.9. The comparable SUVmax figures now are 1.9, 1.6 and 1.3.

The report said it was consistent with high-grade disease, fortunately a biopsy confirmed no high-grade transformation. My FL has always been very lively unfortunately.

I now have nine further Epcoritamab injections, one every 28 days rather than weekly, and continue to take Lenalidomide for 21 days out of every 28. The clinical trial is the Refract study under Dr Kim Linton.

After that, it’s all about how long it stays away. How will remission compare to chemo??

This is my 4th line treatment in ten years after RCVP, RCHOP & auto SCT and R squared.

Immunotherapy is the future. I’m sure Bispecfics will be used first line one day (and can be used more than once), with CAR-T then for difficult to treat disease, and chemo to try if all else fails.